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Abstract
Background: Current guidelines for dementia care recommend the combination of drug therapy
with non-pharmaceutical measures like counselling and social support. However, the scientific
evidence concerning non-pharmaceutical interventions for dementia patients and their informal
caregivers remains inconclusive. Targets of modern comprehensive dementia care are to enable
patients to live at home as long and as independent as possible and to reduce the burden of
caregivers. The objective of the study is to compare a complex intervention including caregiver
support groups and counselling against usual care in terms of time to nursing home placement. In
this paper the study protocol is described.
Methods/Design: The IDA (Initiative Demenzversorgung in der Allgemeinmedizin) project is
designed as a three armed cluster-randomized trial where dementia patients and their informal
caregivers are recruited by general practitioners. Patients in the study region of Middle Franconia,
Germany, are included if they have mild or moderate dementia, are at least 65 years old, and are
members of the German AOK (Allgemeine Ortskrankenkasse) sickness fund. In the control group
patients receive regular treatment, whereas in the two intervention groups general practitioners
participate in a training course in evidence based dementia treatment, recommend support groups
and offer counseling to the family caregivers either beginning at baseline or after the 1-year follow-
up. The study recruitment and follow-up took place from July 2005 to January 2009. 303 general
practitioners were randomized of which 129 recruited a total of 390 patients. Time to nursing
home admission within the two year intervention and follow-up period is the primary endpoint.
Secondary endpoints are cognitive status, activities of daily living, burden of care giving as well as
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healthcare costs. For an economic analysis from the societal perspective, data are collected from
caregivers as well as by the use of routine data from statutory health insurance and long-term care
insurance.
Discussion: From a public health perspective, the IDA trial is expected to lead to evidence based
results on the community effectiveness of non-pharmaceutical support measures for dementia
patients and their caregivers in the primary care sector. For health policy makers it is necessary to
make their decisions about financing new services based on strong knowledge about the acceptance
of measures in the population and their cost-effectiveness.
Trial registration: ISRCTN68329593
Background
Dementia care is one of the most important challenges for
health care systems in the greying societies of – for exam-
ple – the US or Europe. Based on epidemiological prog-
noses they will have to cope with doubled or tripled
figures of dementia patients until 2050 [1-3]. In Germany,
direct medical costs for patients with dementia totalled
6.1 billion Euros in 2004 which made up 2.7% of total
direct medical cost. Institutional care for patients with
dementia accounted for 3.9 billion Euros [4]. Hallauer
and colleagues calculated that the average total costs per
patient including informal care sum up to approximately
44,000 Euros per year in Germany, of which the monetary
equivalent of informal care giving time is the largest share
[5]. From a societal and public health point of view, there
is need to implement evidence based standards and serv-
ices of medical and social care for patients and their car-
egivers [3].
Looking at current clinical dementia guidelines, there
seems to be sufficient evidence for the efficacy of some
drugs (e.g. cholinesterase inhibitors) in symptomatic ther-
apy aiming at the delay of the disease progress. However,
the scientific evidence concerning non-pharmaceutical
interventions for dementia patients and their informal
caregivers remains inconclusive [6-15]. Reasons can be
found in the heterogeneity of intervention types, popula-
tions, settings, study designs, outcomes and – in addition
– in widespread methodological quality problems, e.g.
small sample sizes, observation periods too short to see
clinically relevant intervention effects, and further short-
comings of scientific evaluation [6,7]. In a recently pub-
lished meta analysis, an overall significant positive effect
of non-pharmacological interventions in delaying institu-
tionalization was reported, but there was significant het-
erogeneity between the thirteen studies [16]. While the
cost-effectiveness of anti-dementive drugs is frequently
analyzed, only few economic evaluations exist for non-
medical interventions aiming to postpone institutional
care [17-23].
Because in Germany general practitioners (GPs) play the
key role in health care of the elderly, they automatically
come into focus when introducing new services in demen-
tia care. In most cases GPs are primarily faced with essen-
tial tasks like detecting and diagnosing dementia,
information of patient and family members, drug therapy,
and linking to further counselling and supportive meas-
ures. Especially in the care of non-institutionalized
dementia patients, the GPs' influence on the help seeking
behaviour of patients and caregivers can be decisive for
families' willingness to accept external support and expert
counselling. A systematic interdisciplinary collaboration
between GPs, medical specialists and professionals in the
field of social and psychological dementia care will be a
key issue in the future [24].
In current practice the context of dementia care is difficult
and study results [25-31] hint on the existence of a bundle
of factors related to patient, caregiver, and physician
which are building a barrier for optimizing dementia care.
On the societal level, dementia is a stigmatized disease
surrounded by influences of ageism. Patients and caregiv-
ers often deny dementia symptoms, experience difficulties
in accepting the diagnosis, and react to the disease with
social withdrawal and depression. They have a lack of dis-
ease specific knowledge and of information on regional
support and counselling services. This lack of knowledge
is often shared by their GPs [32] who have a tendency of
tabooing cognitive impairments and have difficulties in
telling bad news – especially disclosing a diagnosis of
dementia [33-36]. Furthermore, a skeptical or negative
attitude towards the potential benefits of dementia drug
therapies [37] and the unclear evidence concerning non-
pharmaceutical treatment and support options as well as
unclear referral ways to specialist psychiatric services (e.g.
memory clinics) may prevent the optimal care for demen-
tia patients.
All these above mentioned factors in sum lead to delayed
and insufficient care with regard to diagnostics, treatment,
counselling and social support for many dementiaBMC Health Services Research 2009, 9:91 http://www.biomedcentral.com/1472-6963/9/91
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patients [3,26]. Therefore, a potentially successful inter-
vention program in primary care has to address several of
these obstacles to optimize dementia care. Focussing on
single factors like education and training programs for
doctors or distribution of dementia guidelines to close
GPs' knowledge gaps probably is not enough [38-40].
The IDA study aims to combine several treatment options
including training of GPs concerning diagnosis and treat-
ment of dementia, out-patient specialist support for GPs,
the offer of support programs and counseling for informal
caregivers of patients with dementia.
The main research questions of the IDA project, from the
perspectives of health care and health economics, are: (1)
Is a complex intervention for community dwelling
dementia patients, their caregivers and doctors more effec-
tive than usual care with respect to postponement of nurs-
ing home placement? (2) Does the intervention have an
effect on disease progression and on caregiver burden? (3)
Is the intervention cost-effective compared to usual care
when assessed from the societal perspective? The objective
of this paper is to describe the study protocol of the clus-
ter-randomized IDA study. Recruitment and follow-up of
all study patients have ended and the analysis phase has
started by spring 2009. The detailed description of the
study background and protocol is published as a reference
for forthcoming papers describing the study results.
Methods/Design
Study Design and Setting
The IDA study is designed as a three-armed cluster-rand-
omized trial. The main research hypothesis is that for
dementia patients still living at home a complex interven-
tion consisting of an initial training of GPs in evidence
based diagnosis and treatment, of the provision of car-
egiver support groups, and of actively approaching family
counselling, can prolong time to nursing home placement
in comparison to usual care. In comparison to usual care
(study arm A), one intervention group receives additional
training of GPs in medication and non-medication based
therapies for dementia, and caregivers are offered to par-
ticipate in caregiver support groups (study arm B),
whereas in the second intervention group actively
approaching family counselling is additionally imple-
mented (study arm C). The duration of the intervention
phase is two years. However, a change of study design
became necessary due to the unexpected slow recruitment
of patients (18 months instead of 6 months) and the very
low participation rates of caregivers in the caregiver sup-
port groups. The main focus of the study was shifted
towards the comparison of groups A and C. In group B,
the actively approaching family counselling was imple-
mented after the 1-year follow-up. Thereby, patients in
arm B can serve as an intermediate intervention group in
the first year and as an additional full intervention group
in the second year. The new study design is shown in Fig-
ure 1.
The study region Middle Franconia is a mixed urban rural
area around Nuremberg in Bavaria, Germany.
Recruitment of GPs and Patients
All GPs in the study region in Middle Franconia (about
1200) were contacted with an information leaflet and
invited to participate in the project. GPs willing to partic-
ipate had to sign a contract with the AOK sickness fund.
The training sessions (one for each GP) took place with
groups of 10 to 30 GPs.
After the training, the GP identified all dementia patients
in his or her practice who fulfilled the following selection
criteria. Patients were included if they had mild to moder-
ate dementia as defined by an MMSE (Mini Mental State
Examination) between 10 and 24 [41], if they were at least
65 years old and a member of the AOK health insurance,
and if they still lived at home and had an informal car-
egiver who was willing to participate in the study. The
MMSE is a widely used test of cognitive function. Patients
with a MMSE score below 10 were excluded because they
were considered to be unable to give informed consent. In
addition, we expected that in these patients nursing home
placement could be necessary before treatment could
have any effect. Patients with a MMSE score above 24 were
excluded to gain a certain level of diagnostic accuracy and
reduce the rate of falsely included patients with mild cog-
nitive impairment (MCI), because a differential diagnosis
is often difficult for GPs. Patients were excluded if they
had terminal illness or if admission to nursing home was
already planned. Patients not able or not willing to give
informed consent were also excluded. Patients could be
newly diagnosed or were already known as dementia
patients.
Signed informed consent of study participants and their
informal caregivers was required before patients could be
entered into the study. The study protocol as well as the
amendment necessitated by the change in study design
has been approved by the Ethics Committee at the Bavar-
ian Chamber of Physicians. (Date of approval: 30/05/
2005, Reference number: 05029). Furthermore, the study
is conducted in accordance to German privacy law and in
compliance with the Helsinki Declaration. Recruitment of
patients started in June 2005 and ended in December
2006.
Randomization
The IDA project is a cluster-randomized study where the
general practices are the clusters and thus the units of ran-
domization. If two or three GPs from the same groupBMC Health Services Research 2009, 9:91 http://www.biomedcentral.com/1472-6963/9/91
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practice wanted to participate in the study and attended
the training course, they were randomized into the same
study arm. The randomization was done by the statistics
and data centre, usually one day before each training
course when the full list of registered participants was
available. We applied the randomization method of per-
muted blocks within strata, where stratification was done
with respect to study region and type of practice (single vs.
group). The allocation ratio was 1:1:1. The GPs were
informed about their assigned study arm during the train-
ing course.
Interventions
The study arm A serves as a control group where patients
receive usual care. However, since GPs served as mediators
of the intervention in IDA, all participating GPs received
at least basic information concerning dementia diagnosis
and about study procedures.
Training GPs
The obligatory training course for all participating GPs
consisted of a dementia-specific part and a part concern-
ing the study.
The dementia-specific part of the training consisted of
dementia diagnostics including execution of the Mini-
Mental Status Examination (MMSE) with a video demon-
stration and a section about patient and caregiver infor-
mation (120 minutes). Afterwards, the GPs were
informed to which study arm they were randomized. GPs
of study arm A were separated from B and C and received
study-specific information. Group A physicians were
trained in early detection and diagnosis of dementia only.
Their knowledge of non-medical treatment options and
drugs was not part of the initial training. As a comparator
this level of knowledge could serve as a proxy for the gen-
eral status quo. The diagnostic training contained basic
information about dementia (epidemiology, pathophysi-
Study design Figure 1
Study design.
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Further training on diagnosis of dementia
Further training on therapy of dementia
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ology, early symptoms of dementia), anamnesis and
physical examination, laboratory diagnostics, and psy-
chometric tests. The additional training for group B and C
physicians on treatment of dementia (140 minutes) con-
sisted of information about interfaces in the German
health care system, non-medication based treatment,
information and counselling of caregivers, medical treat-
ment options, therapy of non-cognitive disorders and spe-
cific problems. The dementia guideline for GPs, published
by the Witten-Herdecke University http://www.evi
dence.de and the therapy recommendations of the Phar-
maceutical Commission of the German Medical Associa-
tion were used as the basis of the training. The therapeutic
and diagnostic part of the training was given by five neu-
rologists or psychiatrists with proven gerontopsychiatric
expertise who are active in out-patient care in the study
region.
All doctors received a folder containing written informa-
tion specific to groups A, B, or C of the study including the
slides of the training, the current dementia guideline and
the baseline documentation forms for 10 patients.
Out-patient specialist support for GPs
The medical experts involved in the training offered out-
patient consultant support to the GPs in groups B and C.
In the case of acute deterioration or problems with ther-
apy, appointments were available for dementia patients at
short notice. Additionally a weekend telephone consult-
ant on-call service was set up for the GPs.
Recommending family caregiver support groups
In groups B and C, the GPs suggested that caregivers
should attend a family caregiver support group. The car-
egiver received an information sheet from the GP with
contact details of 17 family caregiver support groups
within the study region, all of which had been set up inde-
pendently from the IDA project. The groups were required
to have three qualifying characteristics: (1) professional
supervision, (2) hold at least ten formal meetings per year,
and (3) contain a psycho-educational element to improve
the competencies of the family caregivers. After the con-
sultation, the GP sent a fax to the chosen family caregiver
support group, so that it would be possible to verify later
which relatives attended a support group following the
GP's offer. The family caregiver alone decided whether the
visit actually took place or not.
"Counsellors contact caregivers" (CCC)
The family caregivers in Group C (and in group B after one
year as well), were offered a special type of family car-
egiver counselling which would be recommended to them
by their GP. After receiving the registration fax from the
GP, the counsellor (now referred to as the "IDA counsel-
lor") contacted the family caregiver by phone and tried to
establish personal contact in form of a home visit, if pos-
sible. The IDA counsellor used elements of case and care
management in educating and supporting the family car-
egivers psychologically and socially, to improve their
competences in all facets of care. The aim was to support
the family caregiver to the extent that the dementia patient
was able to remain in the domestic environment as long
as possible. Guidelines were developed for choosing those
supportive measures that were expected to have a positive
effect in specific situations. The IDA counsellor was also
available by phone on weekends.
Four IDA counsellors worked in the project. Their profes-
sional competence consisted of training and several years
of experience in nursing. They were expected to be able to
empathise with the family caregivers and they received
regular training in subjects important for the counselling
process. Because of the large study area, the care managers
were assigned to the patients regionally.
Measurements
The study outcome variables concern potential effects of
the intervention on the patient and on the caregiver level.
In addition, economic outcomes from a societal perspec-
tive are registered.
The primary endpoint of the study is the remaining time
the patient lives at home. This is defined as time from
study entry until either nursing home placement (for at
least 8 weeks) or death. In an additional analysis, death
will be treated as a censoring event.
Secondary endpoints are:
1. Cognitive functioning of the patients (MMSE)
2. Patients' ability to perform ADL and IADL measured
by the Barthel-Index [42] and the IADL subscale of the
Nurses' Observation Scale for Geriatric Patients NOS-
GER [43]
3. Subjective burden of informal caregivers measured
by the Burden Scale for Family Caregivers (BSFC) [44]
4. Quality of life of the patients (EQ-5D) [45-47]
5. Time to death
6. Number and duration of hospital stay
7. Direct medical and non-medical costs (including
informal care)
8. Use of formal care and support servicesBMC Health Services Research 2009, 9:91 http://www.biomedcentral.com/1472-6963/9/91
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Table 1 gives an overview on baseline and follow-up
measurements. The measurements in the IDA project
occur at the following fixed and variable time points:
baseline measurement at entry into study (t0), follow-ups
at six months (only for patients in arm B and C if they
receive an antidementive drug) (t6), at twelve months
(t12) and after 24 months (t24). If the patient was admitted
to nursing home, no further assessments took place but
GPs and caregivers were asked about the reasons for the
institutionalization.
The baseline assessment (t0) consisted of the documenta-
tion by the GP including test results and a telephone inter-
view with the primary caregiver. In accordance with a
naturalistic study design, documentation was restricted to
an essential set of variables. The computer-aided tele-
phone interview with the informal caregiver was con-
ducted by trained interviewers. Apart from the Barthel-
Index, NOSGER, and BSFC items, the telephone interview
contains detailed assessment of informal care time and
the use of formal care by home care services. If the inter-
viewees refused to respond by telephone, they were asked
to answer a written version of the questionnaire.
Economic data
The cost-effectiveness of the intervention will be calcu-
lated from a societal perspective. Table 2 shows the differ-
ent data sources for the assessment of resource use and
direct cost. All patients, as well as caregivers who are
insured with the same sickness fund, were asked to give
permission to get their health insurance data over a time
period covering one year before and four years after study
entry.
The informal care time of all involved caregivers is
assessed within the telephone interview with the primary
caregiver. We used an extended version of the specific
questions on informal care time of the Resource Utiliza-
tion in Dementia (RUD)-instrument [48,49]. Formal and
informal care was assessed by days during the last four
weeks and average number of hours on these days. Costs
not reimbursed by the health insurance were additionally
assessed.
Intervention costs will be estimated, these include costs
for care managers (including labour costs and overhead
costs) and for caregiver support groups. Study specific
costs, which would not occur in routine application, will
not be considered.
Measures against bias
The study is unblinded with respect to the GPs, the
patients, and their caregivers. However, the assessment by
telephone interview after one and two years is done by
students who are not informed to which study arm the
patient belongs.
Table 1: Baseline and follow-up measurements
Aim Instrument Applied to t0 t6 t12 t24 th
Anamnestic data Baseline CRF GP X
Quality of life of patient EQ-5D Patient, informal caregiver and GP X X X
Cognitive function patient MMSE GP X X X X
DEMTECT GP X
Evaluation of antidementiva therapy CRF GP X
Global health status of the patient CGI GP X X X X
Behavioural problems patient NOSGER (Subtest) Informal caregiver X X X
ADL patient Barthel-Index Informal caregiver X X X
IADL patient NOSGER (Subtest) Informal caregiver X X X
Caregiver burden BSFC Informal caregiver X X X
Resource use, situation of caregiver Questionnaire Informal caregiver X X X
Nursing home placement (reasons) Questionnaire Informal caregiver and GP XBMC Health Services Research 2009, 9:91 http://www.biomedcentral.com/1472-6963/9/91
Page 7 of 11
(page number not for citation purposes)
From the methodological point of view, the main prob-
lem with cluster randomized trials is the potential for
selection bias [50]. Although the GPs are randomly
assigned to the study arms, inclusion of patients and their
caregivers may be biased by foreknowledge of the alloca-
tion. This can occur because doctors may differently
approach patients depending on the study arm they
belong to or because patients and caregivers may differ-
ently consent to participation.
To address the problem of selection bias, we asked the
participating GPs to initially provide a list of all dementia
patients in their practice whom they considered eligible
for the study. These lists will allow comparison of the
basic characteristics of patients participating vs. those not
included in the study overall and between study arms.
Analysis
The confirmatory analysis of the study concerns the com-
parison of the three study groups with respect to the pri-
mary endpoint. To account for multiple testing, we plan
to apply a closed testing procedure, which consists of test-
ing the global null hypothesis of no difference between all
three groups, and, in case of rejection, three subsequent
pairwise comparisons with a significance level of 5%.
Since the primary endpoint is a censored failure time var-
iable, survival models adapted for clustered data will be
applied [51]. All analyses will primarily be done accord-
ing to the intention-to-treat approach. Analyses of second-
ary endpoints will use generalized linear models
accounting for cluster randomization. Selection bias will
be tested and adjusted for on the basis of available base-
line data. For most secondary endpoints, no measure-
ments will be available if the patient has died or moved
into a nursing home. These analyses will therefore be
done on the basis of all available cases. Additional analy-
ses will be performed by applying imputation methods to
those cases where patients were admitted to nursing
home. In case of severely skewed distribution of cost vari-
ables, we will check the robustness of results by applying
transformations or by performing bootstrap analyses.
Sample size
For the sample size calculation, we had to consider a mul-
tiple test procedure for a three-group comparison with
respect to a censored outcome variable and with allow-
ance for a cluster effect. The calculation was based on an
error probability α = 0.05 and a statistical power 1-β =
0.90 for each of the pairwise comparisons. As a clinically
relevant effect we considered a difference of 15% or more
in the probability a patient is still living at home after two
years. The AD2000 Collaborative Group reported that
25% of the dementia patients had to be moved to a nurs-
ing home after two years [52]. This rate was used as event
rate for study arm B. As deaths are counted as event we
assumed a 10% point higher rate in all study arms. Under
the alternative hypothesis we estimated that 50% (arm A,
usual care) vs. 65% (arm B) vs. 80% (arm C) would still
live at home after two years. As a result, 227 patients per
arm were needed for a study with individual randomiza-
tion [53]. Allowing for a cluster effect (ICC = 0.05, correc-
tion factor = 1.2) yields 272 patients per group. With
further allowance for drop-out (10%) we decided to set
the recruitment target at 900 patients. The change in study
design reported above was considered acceptable with
respect to statistical power, since a power of 75% could
still be achieved for the comparison of groups A and C
with a sample size as small as 120 per group if a 20% dif-
ference in event rates was assumed.
Table 2: Data sources for cost estimation
Category Source
Outpatient care Health insurance data
Prescribed drugs Health insurance data
Inpatient care Health insurance data
Rehabilitation Health insurance data
Medical aids and non-physician services Health insurance data and caregiver interview
Informal care Caregiver interview
Other dementia-related costs not reimbursed by the health insurance including self-paid drugs Caregiver interview
Formal care and support services Health insurance data and caregiverBMC Health Services Research 2009, 9:91 http://www.biomedcentral.com/1472-6963/9/91
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Economic evaluation
The primary economic evaluation will be a cost-effective-
ness analysis from the societal perspective. The results will
be presented as incremental cost per additional year living
at home. We will use the bootstrap approach to calculate
confidence intervals for incremental cost-effectiveness
ratios. In a secondary cost-utility analysis, quality-
adjusted life years (QALYs) will be calculated based on
EQ-5D values.
Discussion
In this paper we describe the study design of an innovative
cluster-randomized trial evaluating the cost-effectiveness
of a complex intervention for GPs and family caregivers of
patients with dementia living at home. The IDA study
aims to combine several treatment options including
training of GPs concerning diagnosis and treatment of
dementia, out-patient specialist support for GPs, and sup-
port programs and counseling for informal caregivers of
patients with dementia. The counseling for caregivers is
the main intervention of the IDA study.
Particular strengths of the study design are the relatively
large sample size, the cluster randomization, the long fol-
low-up of two years, and the availability of complete
health insurance data for all patients over the whole study
period. Since we planned this study as a so-called prag-
matic (or naturalistic) trial, we tried to aim at maximum
generalizability by recruiting a large number of GPs who
cover a mixed urban and rural region typical for Germany.
We motivated participating GPs to include all suitable
patients in the study. Formal inclusion and exclusion cri-
teria for patients, such as availability of caregiver, were
necessary and do not pose a threat to external validity.
Restriction of patients to those from the AOK sickness
fund seemed necessary, since we wanted to obtain com-
plete health insurance data. This is no severe threat to
external validity, since the regional AOK sickness funds
have the largest share of insured patients in Germany. In
2005, about one million people or 49.6% of the popula-
tion aged over 65 of the statutory health insurance market
in Bavaria was insured by the AOK.
The major problem with respect to selection bias is the
exclusion of patients whose caregivers are not willing to
participate, either because of fear of stigmatization or
other reasons. Some GPs may be more willing and able to
convince patients and caregivers to participate than oth-
ers, and in a cluster randomized trial this may also be
related to the treatment group. In order to investigate
selection bias, we plan to compare groups with respect to
baseline data. In addition, we asked all GPs to initially
provide a list of patients they would approach. In a sub-
sample of about 50% of all GPs we conducted interim tel-
ephone interviews to ask them about progress of
recruitment and reasons for non-inclusion.
Since patients with dementia may not be able to give cor-
rect information, we collected all data via GPs or caregiv-
ers or from the sickness fund. The only exception is
assessment of quality of life, which was also collected
from patients.
We chose time to nursing home referral as the primary
endpoint because the main concept was to help caregivers
to care for their relatives suffering from dementia as long
as possible in their living environment. In a recent meta-
analysis only studies were selected that reported this end-
point [16]. We discussed in detail whether death before
nursing home placement should be included in the pri-
mary endpoint or count as a censoring event. Other stud-
ies often do not explicitly mention how this is handled as
for instance Spijker et al 2008 [16]. It was decided to
include it because this would minimize any possibility of
bias and we expected to be able to accept the additional
random error because of the large sample size. According
to data from a population based study, median survival
time is five to seven years from time of diagnosis in
patients with mild or moderate dementia [54]. The out-
comes nursing home placement and death can be com-
pletely assessed by AOK data. Reasons for nursing home
placement may be unrelated to progress of dementia, e.g.
caused by other disease or by death of a caregiver. We try
to document these reasons as given by the GP and the car-
egiver wherever possible.
Two year follow-up was considered to be necessary in
order to register enough events within the duration of the
study. In our sample size calculation we expected to
observe 50% events within two years based on estima-
tions from the AD2000 study [52].
There was no additional validation of the dementia diag-
nosis as we decided to choose a naturalistic design. How-
ever, all participating GPs had a training unit in
standardized application of the MMSE.
Physicians prescribe the drug that they consider as the
right one for their patient, reflecting their knowledge of
the disease, the diagnosis and the characteristics of the
patient. In contrast to study arm A, GPs randomized in
study arm B and C were trained in treatment of anti-
dementive drugs. The aim of the training was to improve
the knowledge of the physicians so that the treatment fol-
lows the guideline for GPs (Witten-Herdecke University)
and the therapy recommendations of the Pharmaceutical
Commission of the German Medical Association. There-
fore drug treatment followed evidence-based guidelines
and drugs were prescribed according to their approval.BMC Health Services Research 2009, 9:91 http://www.biomedcentral.com/1472-6963/9/91
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Differential drug prescription may have an additional
intervention effect which cannot accurately be distin-
guished from the effect of the non-medical interventions.
However, the prescribing pattern of the GPs in the three
study arms will be known from the health insurance data
and will be considered in the analysis.
To prevent intervention effects depending on the family
counsellor we implemented a guideline for the counsel-
lors. However, the process of counselling is individual
and depends on many different factors such as the car-
egiver situation, the patients' health status, the living
arrangement etc. Therefore, we cannot guarantee a unique
counselling effect for all counsellors.
We experienced some specific unforeseen problems in the
implementation of the study design that we were able to
solve in a pragmatic way. During recruitment the question
arose how to deal with caregivers who care for two people
meeting the inclusion criteria. We decided that both
patients could take part in the study. Questions within the
telephone interview relating to the informal caregiver
were only assessed once.
It was planned to recruit the primary informal caregiver of
the patient that is the person who carries out the largest
part of informal care. However, sometimes it was not the
primary informal caregiver who signed the written con-
sent. In those cases we refrained from contacting the pri-
mary caregiver and involved the non-primary caregiver. It
might be possible, that their statements on resource use
are less valid as they are not as strongly involved in the car-
ing process as the primary informal caregiver.
Some informal caregivers preferred to answer the print
version of the questionnaire. If the written questionnaires
had values missing, we refrained from contacting these
subjects again. Answers of the written questionnaire
might differ from those of the telephone interview as car-
egivers have not the possibility to pose clarification ques-
tions.
The resource use of informal care is measured since it
plays a substantial role in caring for patients with demen-
tia living at home [55-59]. Omission of costs of informal
care would bias cost-effectiveness against formal care in
favor of informal care which seems to be free of charge
[56]. Measuring the economic burden of informal care is
not easy for several reasons. We decided to assess and
value the time the informal caregivers spent on caring for
the patient. However, sometimes it is not easy to distin-
guish between normal housework and informal care [60].
Furthermore, different methods are available for valuing
that time [61].
However, this kind of valuation does not consider possi-
ble positive effects of care giving for the informal caregiver
[62,63]. However, up to now there is no consent on how
informal care should be incorporated in economic evalu-
ation.
Due to the extension of the recruitment and intervention
time the counselling will be offered to some caregivers for
more than 2 years. This will allow us to analyze effects of
the intervention on nursing home admission beyond the
planned 2-year follow-up. Furthermore, patient and car-
egivers agreed to provide their health care insurance data
for a period of four years after study entry which allows
additional long-term analysis concerning the primary end
point as well as cost from a health care perspective.
From a public health perspective the IDA trial should lead
to evidence based results with regard to the community
effectiveness of non-medical support measures for
dementia patients and their caregivers in the primary care
sector. For health policy makers it is necessary to make
their decisions about financing new services based on
strong knowledge about the acceptance of measures in the
population and their cost-effectiveness.
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